ALK and non-small cell lung carcinoma: This indicated that our SMS model could serve as a well-stratified tool and improve the value of TMB or PD-L1 expression for predicting the prognosis in patients with EGFR/ALK-negative NSCLC receiving anti-PD-1/PD-L1 therapy.